Karyopharm Therapeutics announced that updated clinical data from the Phase 2b STORM study evaluating selinexor, the company’s lead, oral Selective Inhibitor of Nuclear Export compound, in heavily pretreated patients with penta-refractory multiple myeloma, were presented during an oral session at the Society of Hematologic Oncology 2018 Annual Meeting on September 13, 2018, in Houston. Sundar Jagannath, MD, Director of the Multiple Myeloma Program, Professor of Medicine at Tisch Cancer Institute at Mount Sinai School of Medicine, and principal investigator of the STORM study, presented the data in a session entitled, “Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Refractory Myeloma.” “The additional Phase 2b clinical results presented today are very encouraging for the patients suffering from penta-refractory multiple myeloma and their families. Most notably, the overall response rate for patients treated with oral selinexor and dexamethasone was 26.2% with median duration of response of 4.4 months based on the Independent Review Committee assessment, along with a median overall survival across the entire study of 8.6 months,” said Dr. Jagannath. “Of particular significance, for the nearly 40% of patients who had a minimal response or better, the median survival was 15.6 months, which provided the opportunity for a meaningful clinical benefit for patients on the STORM study with advanced penta-refractory myeloma that is difficult to treat.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.